General
Preferred name
ANIDULAFUNGIN
Synonyms
LY303366 ()
Eraxis ()
Ecalta ()
Anidulafungin (LY303366) ()
Anidulafungina ()
LY-303366 ()
D-70013 ()
Anidulafungine ()
VER-002 ()
D70013 ()
VER002 ()
V-echinocandin ()
P&D ID
PD010079
CAS
166663-25-8
66663-25-8
Tags
available
drug
Drug indication
Aspergillosis
Coronavirus Disease 2019 (COVID-19)
Convulsion
Drug Status
approved
Max Phase
4.0
First approval
2006
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Anidulafungin is a new semisynthetic echinocandin with antifungal potency.
DESCRIPTION Anidulafungin (Ecalta) (LY303366) is an echinocandin derivative used as an antifungal drug. It inhibits glucan synthase activity. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
13
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugMAP Approved Drugs
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
107
Properties
(calculated by RDKit )
Molecular Weight
1139.51
Hydrogen Bond Acceptors
17
Hydrogen Bond Donors
14
Rotatable Bonds
14
Ring Count
7
Aromatic Ring Count
4
cLogP
-0.93
TPSA
377.42
Fraction CSP3
0.47
Chiral centers
15.0
Largest ring
21.0
QED
0.07
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Microbiology/virology
Anti-infection
Indication
candidemia, fungal infection, esophageal candidiasis
MOA
fungal 1,3-beta-D-glucan synthase inhibitor
Biosynthetic Origin
Peptide (NRPS)
Therapeutic Indication
Antifungal
Therapeutic Class
Antimicrobial
Antifungal Agents
Antiviral Agents
Target
Fungal
antibiotic
glucan synthase
Source data